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Abstract We explored the impact of patient demo-
graphics, anthropometric measurements, cardiovas-
cular risk factors, and soluble biomarkers on necrotic
core and atheroma size in patients with coronary
disease. The IBIS-2 trial enrolled 330 patients. In the
multivariate analysis, at baseline, creatinine had a
positive, whereas baseline mean lumen diameter and
myeloperoxidase had a negative, independent asso-
ciation with percentage of necrotic core (PNC); while
age, glomerular filtration rate \60, HbA1c, previous
PCI or CABG and baseline % diameter stenosis were
positively, and acute coronary syndromes (ACS)
were negatively associated with baseline percentage
atheroma volume (PAV). The variables associated
with a decrease in PNC from baseline were darapla-
dib, ACS and a large content of NC at baseline, while
variables associated with an increase in PNC were
previous stroke and % diameter stenosis at baseline.
Those variables associated with a decrease in PAV
from baseline were waist circumference, statin use,
CD40L and baseline PAV, while the only variable
associated with an increase in PAV was baseline
diastolic blood pressure. Treatment with darapladib
was associated with a decrease in necrotic core, but
was not associated with a decrease in percentage
atheroma volume. On the contrary, statin use was
only associated with a decrease in percentage ather-
oma volume.
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Introduction
Cardiovascular (CV) disease remains the principal
cause of death worldwide, with three-fourths of CV
deaths attributed to atherosclerosis. Pathological
studies in patients who have died from coronary
heart disease (CHD) show extensive evidence of
coronary atherosclerosis [1]. The current paradigm
suggests that the main cause of cardiac death is
primarily due to rupture of an advanced atheroscle-
rotic lesion [2]. Ruptured plaques contain the largest
amount of necrotic core (NC) among atherosclerotic
lesions, suggesting a link between the amount of NC
and their predisposition to rupture [3]. In fact, the
area of necrotic core in thin capped fibroatheromas
(TCFA) is 1.6 ± 1.8 mm2 and in ruptured plaques is
2.2 ± 1.9 mm2 respectively [3].
Anthropometric measurements and conventional
CV risk factors relate to the risk of subsequent CV
events as demonstrated by the original Framingham
cohort, and more recently by the INTERHEART multi-
ethnic study on the predictors of the first myocardial
infarction (MI) [4, 5]. Notwithstanding these observa-
tions, accurate prediction of major coronary events on
an individual patient level, as opposed to population
based studies, remains challenging. Therefore, there is
an interest in additional markers of patient vulnerabil-
ity that would enhance precision of risk estimation
beyond that afforded by the Framingham risk score or
other conventional risk assessment tools. The ability to
quantify NC in vivo by the intravascular ultrasound
radiofrequency (IVUS-RF) data analysis offers the
opportunity to provide unique information about
plaque type to enhance the precision of clinical and
laboratory variables used to assess CV risk. Although
the ultimate validity of this measurement will require
very large and long-term natural history studies, the
first step is to examine the relationship between patient
derived variables and NC and extension of coronary
atheroma. Accordingly, we sought to explore in vivo
the relationship between patient demographics, anthro-
pometric measures, CV risk factors, soluble biomark-
ers and plaque composition (percentage of necrotic
core) or its overall size (percentage atheroma volume).
Methods
Study design
The Integrated Biomarkers and Imaging Study-2 trial
has been published elsewhere [6]. Briefly, it was an
international, multicenter, randomized, double blind,
placebo-controlled study in patients with confirmed
CHD. Institutional review boards at each center
approved the protocol, and patients provided written
informed consent. Within 10 days of cardiac cathe-
terization, eligible patients who were clinically stable
were randomized to oral doses of darapladib EC
160 mg (GlaxoSmithKline) or placebo once daily
(1:1 ratio) for the 12 months treatment period.
Patient population
Patients 18 years of age or older undergoing cardiac
catheterization for acute coronary syndrome (ACS—
non-ST-elevation and ST-elevation MI) or non-ACS
(e.g, chronic stable angina or troponin-negative resting
chest pain) were eligible. The protocol specified that
50% of randomized patients were to have troponin-
positive ACS. The randomization was stratified
according to ACS status and center. Key exclusion
criteria were planned surgical revascularization, stroke
in the past 6 months, chronic hepatic disorder or
abnormal ALT, bilirubin (ALT [ 2.5 or bilirubin [
1.5 upper limit of normal), serum creatinine [ 2.0 mg/
dL, blood pressure [ 160/100 mmHg, poorly con-
trolled diabetes mellitus (HbA1c [ 10%), severe heart
failure or left ventricular ejection fraction\30%, and
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current life-threatening condition. Patients were inel-
igible if angiography demonstrated left main coronary
stenosis [50% or if coronary anatomy was inappro-
priate for IVUS.
IVUS imaging
The ECG-gated IVUS-RF acquisition was performed
using EagleEye catheter (20 MHz) at pullback speed
of 0.5 mm/sec. The quantitative IVUS analysis was
performed by the Core Imaging Laboratory (Cardi-
alysis, Rotterdam, The Netherlands) using custom-
ized software (pcVH 2.1, Volcano Corporation). The
analyst selected the region of interest flanked by the
presence of easily identifiable anatomical landmarks.
Vessel and lumen area data were obtained for
every cross-section throughout the region of interest
by semiautomatic planimetry of the leading edges of
the luminal and external elastic membrane borders.
The composition of coronary atheroma was assessed
using spectral analysis of backscatter RF signals
(Fig. 1). Necrotic core was identified with an auto-
regressive classification system that showed a sensi-
tivity and specificity of 92 and 97% for detection of
necrotic core, respectively. To assess intra- and inter-
observer variability of necrotic core measurements,
20 patients from the current study (2,465 frames)
were analyzed twice by two different analysts. The
mean absolute difference for necrotic core area was
0.01 mm2 (SD 0.06) for the intra-observer, and
0.02 mm2 (SD 0.08) for the inter-observer variability,
respectively.
Study end point definitions (IVUS-RF)
Atheroma area contains both atherosclerotic plaque
and media. This was obtained after planimetry was
completed at the lumen/plaque boundary and at the
media/adventitia boundary in each cross-section
forming the region of interest. Percent atheroma
volume was derived by dividing the total atheroma
volume by the total vessel volume and multiplying by
100.
The necrotic core area was automatically obtained
in each cross-section forming the region of interest
using dedicated software (pcVH 2.1, Volcano Ther-
apeutics). Necrotic core values were expressed in
mm2. In addition, the percentage of necrotic core was
calculated as the percentage of the total tissue type
components.
Biomarkers
Plasma hsCRP was measured as described previously
[7]. Plasma Lp-PLA2 activity was measured by a
colorimetric method [7]. Other biomarkers (IL-6,
MPO, ICAM-1, and MMP-9 activity) were assayed
using commercially available kits. Oxidized
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Fig. 1 The ultrasound signal is generated in a piezoelectric
crystal (asterisk) that transmits and receives sound waves (a).
Ultrasound reflected by the tissue deforms crystal generating
radiofrequency (RF) signal (b). Greyscale IVUS is derived
from the amplitude of RF signal, discarding information
beneath the peaks of the signal (c). Changes in the electric field
of the piezoelectric crystal caused by ultrasound reflection is
used to generate a grey-tone image (d). IVUS-RF analysis uses
several additional spectral parameters to identify four plaque
components (e). Plaque components that are identified are
dense calcium (white), fibrous (green), fibro-fatty (greenish-
yellow) and necrotic core (red) (f). PAV percentage atheroma
volume, EEM external elastic membrane, CSA cross-sectional
area
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phospholipid content per particle of apoB (oxPL/
apoB) was measured using murine monoclonal
antibody E06 as described [8]. Platelet biomarkers
were measured in plasma (P-selectin, CD40L) [7].
Endothelial function
Endothelial function was assessed using peripheral
artery tonometry (PAT). PAT is a noninvasive
method that uses automated technology to obtain
continuous data monitoring of the peripheral arterial
pulse waveform by use a finger-mounted pneumatic
sensor (Endo-PAT 2000, Itamar Medical). The mag-
nitude of the waveform is dependent on vascular
compliance. Endothelial function is assessed by
changes in compliance after period of ischemia
followed by reperfusion. A ratio of the amplitude
prior and after occlusion is calculated and corrected
for baseline value and a second sensor is used as a
control on the non-occluded extremity.
Statistical analysis
Necrotic core as a percent of VH plaque and percent
atheroma volume (both baseline and change from
baseline) were the dependent variables explored in
these analyses. A total of 39 covariates were consid-
ered in the univariate regression analyses. In addition,
treatment group and baseline value were considered
in the analyses of change from baseline. All class
variables, except gender, were coded [0,1] with 0 for
absence or 1 for presence. Gender was coded 0 for
females and 1 for males. The set of variables with a
p value of B0.10 in the univariate regression analyses
were included in the multivariate regression analyses.
Both backward selection and forward selection were
used, and the entry criterion and stay criterion were
set to 0.05.
Statistical analyses were performed with use of
SAS V9.1.3.
Results
Between November 16th, 2005 and August 16th,
2006, 330 patients were enrolled.
There are 239 subjects with a value for change
from baseline in % necrotic core and there are 262
subjects with a value for change from baseline in %
atheroma volume. Table 1, which has been published
previously characterizes the population and is based
on the ITT population (N = 323) [6]. Mean length of
the IVUS pullbacks was 50.3 ± 16.8 mm.
Univariate association between baseline
characteristics and plaque morphology
The list of variables (only those with a p value
\ 0.10) and their univariate association with percent-
age necrotic core (PNC) area and percentage ather-
oma volume (PAV) is shown in Tables 2 and 3.
Multivariate association between baseline
characteristics and plaque morphology
In the multivariate analysis, at baseline, creatinine
had a positive, whereas baseline mean lumen diam-
eter and myeloperoxidase a negative, independent
association with PNC. Age, GFR \ 60, HbA1c,
previous percutaneous or surgical coronary revascu-
larisation and baseline % diameter stenosis were all
positively associated with baseline PAV, whilst ACS
had a negative association (Table 4).
Multivariate association between baseline
characteristics and change from baseline in plaque
morphology
The variables associated with a decreased PNC from
baseline were darapladib, ACS and a large content of
NC at baseline, while variables associated with an
increase in PNC were previous stroke and % diameter
stenosis at baseline. The variables associated with a
decrease in PAV from baseline were waist circum-
ference, statin use, CD40L and baseline PAV, while
the only variable associated with an increase in PAV
was diastolic blood pressure (Table 4).
Discussion
In non-culprit vessels, large baseline and necrotic
core rich plaques are associated with a decrease in
percentage of necrotic core at 1 year. Patients with
acute coronary syndrome are more likely to have a
decrease in necrotic core. In this analysis, and after
adjustment for other variables, treatment with dara-
pladib was associated with a decrease in necrotic
Int J Cardiovasc Imaging
123
core, but failed to be associated with a decrease in
percentage atheroma volume. On the contrary, statin
use was only associated with a decrease in percentage
atheroma volume. Thus, patients may need to receive
both drugs to target overall plaque regression and
specifically necrotic core regression.
Our current understanding of plaque biology
suggests that *60% of clinically evident plaque
rupture (i.e. acute coronary syndromes) originates
within an inflamed thin-capped fibroatheroma
(TCFA) [9]. TCFAs are coronary plaques that contain
the largest necrotic core. In living patients, Hong
et al. reported the frequency and distribution of
TCFA identified by virtual histology intravascular
ultrasound in acute coronary syndrome (ACS = 105
pts) and stable angina pectoris (SAP = 107 pts) in a
3-vessel IVUS-VH study. There were 2.5 ± 1.5 in
ACS and 1.7 ± 1.1 in SAP TCFAs per patient,
p \ 0.001. Presentation with ACS was the only
independent predictor for multiple IVUS derived-
TCFA (p = 0.011). Thus, in patients with ACS not
only are necrotic core rich plaques more likely to be
present, but they are also present in higher numbers
when compared to patients with stable angina.
A pathological study has shown that Lp-PLA2
staining was nearly absent in pathologic intimal
thickening plaques; while in complex lesions, such as
Table 1 Baseline Characteristics
Placebo
(n = 151)
Darapladib
(n = 172)
Clinical characteristics
Age (y) 57.3 ± 10.9 59.4 ± 9.8
Males (n, %) 126 (83) 140 (81)
Body-mass index (kg/m2) 27.8 ± 3.8 27.5 ± 4.0
Diabetes mellitus (n, %) 22 (15) 22 (13)
Hypertension (n, %) 89 (59) 115 (67)
Low HDL cholesterol
(\40 mg/dL) (n, %)
40 (26) 45 (26)
Hypercholesterolemia (n, %) 95 (63) 108 (63)
Current smoker (n, %)
Prior medical history (n, %) 57 (38) 64 (37)
Prior myocardial infarction 49 (32) 51 (29)
Prior coronary
revascularization
47 (31) 50 (29)
Peripheral artery disease 7 (5) 17 (10)
Prior stroke 3 (2) 4 (2)
Index hospitalization (n, %)
ACS 74 (49) 87 (51)
STEMI 35 (23) 40 (23)
Non-STEMI 39 (26) 47 (27)
PCI during index
hospitalization
122 (81) 130 (76)
Cardiovascular medications at randomization (n, %)
Aspirin 138 (91) 149 (87)
Clopidogrel or ticlopidine 122 (81) 136 (79)
Any antiplatelet medication 150 ([ 99) 170 (99)
ACE inhibitors or ARBs 88 (58) 101 (59)
Beta-blockers 119 (79) 138 (80)
Statins 134 (89) 157 (91)
Laboratory values
Cholesterol (mg/dL)
Total 187.3 ± 47.6 182.3 ± 43.2
LDL 108.2 ± 41.4 103.6 ± 37.4
HDL 46.8 ± 11.2 48.0 ± 12.4
Triglycerides (mg/dL)
Median 141 136
IQR 97–202 96–193
hsC-reactive protein (mg/L)
geometric mean 2.4 2.4
95% CI 1.9, 3.1 1.9, 3.0
Lp-PLA2 activity (lmol/min/L)
geometric mean 159 160
95% CI 152, 167 153, 167
Blood pressure
Table 1 continued
Placebo
(n = 151)
Darapladib
(n = 172)
Systolic (mm Hg) 125.7 ± 16.9 128.0 ± 16.1
Diastolic (mmHg) 75.2 ± 10.1 75.6 ± 9.9
Study vessela–no. (%)
LAD 44 (36) 56 (39)
LCX 32 (26) 37 (26)
RCA 45 (37) 51 (35)
Diameter stenosisb (%) 28.0 (10.5) 26.6 (10.3)
Mean lumen diameterb (mm) 2.9 ± 0.5 3.0 ± 0.6
Values are presented as mean ± SD unless otherwise
specified; To convert to mmol/L multiply values of
cholesterol by 0.02586 and triglycerides by 0.0113
PCI percutaneous coronary intervention, ACS acute coronary
syndromes
a Imaging evaluable population: placebo 121 patients;
darapladib 146 patients
b Quantitative coronary angiography: placebo 121 patients;
darapladib 144 patients
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thin-cap fibroatheromas and ruptured plaques, an
intense Lp-PLA2 expression within necrotic cores
and surrounding macrophages, including those in the
fibrous cap, was seen [10]. In animal studies, reduced
development of advanced coronary atherosclerosis
has been seen in diabetic and hypercholesterolemic
swine with the use of selective lipoprotein-associated
phospholipase A2 inhibitors (i.e. darapladib) [11].
Specifically, darapladib treatment resulted in a con-
siderable decrease in plaque area and necrotic core
area, and reduced medial destruction, resulting in
fewer lesions with an unstable phenotype.
Necrotic core and cardiovascular risk factors
in pathological studies
Prior attempts to correlate patient characteristics with
plaque morphology assessed during post-mortem
examination are limited by selection bias, (only
patients with fatal events due to coronary or no
coronary causes are included) and often post-mortem
ascertainment of laboratory values. Nevertheless,
history of smoking was associated with evidence of
acute coronary thrombosis (OR 3.6, p = 0.004)
whilst low HDL-cholesterol levels were associated
with plaque rupture (odds ratio for each additional
milligram per deciliter, 1.01) [12]. Diabetes was
shown to be associated with larger necrotic core and
increased macrophage content consistent with the
clinically observed increased risk of CV events in
these patients [13]. The differences with the current
Table 2 List of variables (only with a p value \ 0.10) and
their univariate association with percentage necrotic core
Parameter Parameter estimate
90% CI
p value
Cross-sectional analysis at baseline–percentage necrotic core
Waist circumference 0.063 (0.003, 0.123) 0.085
Netherlands/Belgium 4.733 (2.143, 7.323) 0.003
Czech Republic/Poland 4.030 (1.351, 6.708) 0.014
Germany/Austria/
Denmark
3.775 (1.010, 6.540) 0.025
Norway 4.244 (0.770, 7.718) 0.045
Spain 3.975 (0.337, 7.612) 0.072
GFR \ 60 2.429 (0.020, 4.838) 0.097
Systolic blood pressure 0.047 (0.006, 0.087) 0.057
Hypercholesterolemia -1.474 (-2.825, -0.122) 0.073
Creatinine (nlog) 5.758 (2.717, 8.799) 0.002
Mean lumen diameter -2.449 (-3.755, -1.144) 0.002
Myeloperoxidase -0.932 (-1.773, -0.091) 0.068
Predictors of change from baseline–percentage necrotic core
ACS -1.961 (-3.791, -0.132) 0.078
Statin -3.196 (-6.084, -0.309) 0.069
Previous stroke 6.040 (0.191, 11.888) 0.090
oxPL(n log) 1.191 (0.026, 2.355) 0.093
Circulating p-selection (n
log)
-2.935 (-5.340, -0.529) 0.045
Previous PCI or CABG 2.211 (0.269, 4.154) 0.061
% Diameter stenosis 0.103 (0.014, 0.191) 0.057
Baseline % necrotic core -0.561 (-0.677, -0.445) \0.001
Darapladib -2.038 (-3.872, -0.204) 0.068
Table 3 List of variables (only with a p value \ 0.10) and
their univariate association with percentage atheroma volume
Parameter Parameter
estimate 90% CI
p value
Cross-sectional analysis at baseline–percentage atheroma
volume
Age 0.240 (0.140, 0.339) \0.001
Smoking -3.718 (-5.790, -1.646) 0.003
ACS -3.733 (-5.735, -1.731) 0.002
GFR \ 60 5.541 (1.612, 9.470) 0.021
SBP ( 0.110 (0.047, 0.173) 0.004
IL-6 (n log) 1.103 (0.107, 2.099) 0.069
OxPL (n log) 1.550 (0.251, 2.850) 0.050
HbA1c (n log) 15.075 (6.445, 23.705) 0.004
Previous PCI or CABG 4.770 (2.634, 6.905) 0.003
Creatinine (n log) 6.720 (1.950, 11.491) 0.021
% Diameter stenosis 0.335 (0.245, 0.426) \0.001
Endothelial function 3.721 (0.856, 6.587) 0.033
MMP-9 (n log) -1.331 (-2.630, -0.031) 0.092
Predictors of change from baseline–percentage atheroma
volume
Waist circumference -0.048 (-0.085, -0.012) 0.031
Czech Republic/Poland 2.933 (1.250, 4.616) 0.004
Statin use -2.156 (-3.509, -0.803) 0.009
CD40L (n log) -0.776 (-1.294, -0.257) 0.014
DBP 0.078 (0.037, 0.119) 0.002
Myeloperoxidase (n log) 0.529 (0.014, 1.043) 0.091
Baseline % atheroma
volume
-0.095 (-0.135, -0.056) \0.001
GFR Glomerular filtration rate, oxPL Oxidized phospholipids,
PCI percutaneous coronary intervention, CABG coronary
artery bypass graft, ACS acute coronary syndrome, SBP
systolic blood pressure, IL interleukin, HbA1c Hemoglobin
A1c, MMP Matrix metalloproteinase, DBP diastolic blood
pressure
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study may stem from the fact that our observations
focused on non-culprit vessels. In addition, the
current algorithm for spectral analysis of IVUS-RF
is unable to detect thrombus and lacks precision to
detect inflammatory cell content. Post-mortem mea-
surement of HDL-cholesterol is also fraught with
potential confounding factors.
Plaque size by intravascular imaging and its
relationship with CV risk factors
Several CV risk factors such as male gender, body
mass index (BMI), diabetes and prior coronary
revascularization have been found to be strong
predictors of atheroma volume measured by conven-
tional IVUS. As shown by Nicholls et al. atheroma
volume in women in secondary prevention trials is
smaller, even in the presence of more risk factors [14].
Our study confirms some of these observations
showing an independent association of HbA1C and
prior coronary revascularization with IVUS measure-
ments. Diabetes per se was not an independent
predictor and this is possibly related to the low
number of diabetics enrolled in the current study.
Obesity is an important but complex contributor to CV
morbidity and mortality [15]. Waist circumference,
and simple measures of visceral (abdominal) obesity,
has a superior predictive value for the presence of
CHD or the risk of MI, compared to that of BMI [16].
The large multi-ethnic INTERHEART study showed a
significant relationship between waist circumference
or waist-to-hip ratio and the risk of first MI, even after
full adjustment for other risk factors [5]. Furthermore,
patients with low BMI and increased waist circumfer-
ence have an increased 1-year mortality [17]. In our
study, patients with large waist circumference were
independently associated with percentage atheroma
volume reduction after 1 year.
Despite favourable effects of cholesterol-lowering
therapy with statins in primary and secondary
prevention, a single measurement of serum lipids
did not correlate with IVUS measurements of
percentage atheroma volume or percentage necrotic
core in univariate or multivariate analysis. These
findings are consistent with those reported by others
regarding conventional IVUS measures and do not
contradict halting plaque progression or even its
regression with intensive LDL cholesterol lowering.
In contrast to lipid measurements, renal dysfunc-
tion was related to both larger percentage necrotic
core and larger percentage atheroma volume. Anave-
kar et al. [18] have described that even mild renal
disease should be considered a major risk factor for
cardiovascular complications after an MI. We could
hypothesize that the underlying cause of these events
are necrotic core-rich large plaques.
It is noteworthy that diastolic blood pressure was
shown to be independently associated with plaque
progression by IVUS, and therapeutic interven-
tion(s) aimed at lowering blood pressure below current
guideline mandated thresholds, may retard progression
of atherosclerosis and reduce CV events [19].
Table 4 List of variables (p B 0.05) and their multivariate
association with percentage necrotic core and percentage ath-
eroma volume
Parameter p value estimate
(95% CI)
Variable
Cross-sectional analysis at baseline–percentage necrotic core
Creatinine (lmol/L–n log) 5.7 (1.8, 9.6) 0.004
Mean lumen diameter
(mm)
-2.3 (-3.8, -0.79) 0.003
Myeloperoxidase (n log) -1.2 (-2.2, -0.15) 0.025
Predictors of change from baseline–percentage necrotic core
Darapladib -2.1 (-4.0, -0.22) 0.029
Acute coronary syndrome -2.9 (-4.8, -1.0) 0.003
Previous stroke 8.4 (2.6, 14.2) 0.005
Baseline % diameter
stenosis
0.10 (0.007, 0.19) 0.035
Baseline % NC -0.56 (-0.69, -0.42) \0.001
Cross-sectional analysis at baseline–percentage atheroma
volume
Age (y) 0.12 (0.001, 0.24) 0.049
Acute coronary syndrome -2.6 (-4.9, -0.29) 0.027
GFR \ 60 ml/min 5.1 (0.90, 9.3) 0.017
HbA1c (n log) 12.4 (2.9, 21.9) 0.011
Previous PCI or CABG 3.1 (0.66, 5.6) 0.013
Baseline % diameter
stenosis
0.33 (0.22, 0.44) \0.001
Predictors of change from baseline–percentage atheroma
volume
Waist circumference (cm) -0.05 (-0.09, -0.004) 0.032
Statin Use -2.0 (-3.6, -0.42) 0.013
CD40L (pg/ml) -0.74 (-1.3, -0.15) 0.014
Diastolic blood pressure
(mmHg)
0.09 (0.04, 0.14) \0.001
Baseline % atheroma
volume
-0.09 (-0.14, -0.04) \0.001
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Study limitations
This study is a post-hoc analysis that has a number of
limitations. First, the sample size was small. Second,
the measurements of biomarkers that entered into the
model do not reflect chronic circulating levels, as
50% of patients presented with ACS, which tran-
siently alters levels of inflammatory biomarkers. In
addition, our data indicate that ACS status is not
associated with necrotic core size when assessed in
non-culprit vessels. Although pan-coronary inflam-
mation was reported in ACS patients, IVUS method-
ology is not well suited to measure such endpoints.
Third, some of the measurements are confounded by
concomitant treatments. Fourth, we wish to empha-
size that all IVUS studies are limited to the analysis
of a relatively short segment of coronary arterial tree
that does not fully reflect disease characteristics
elsewhere.
Although independently treatment with darapla-
dib was associated with a decrease in percentage
necrotic core and statin use was only associated with
a decrease in percentage atheroma volume, the
interaction factor between statins and darapladib for
the relationship between changes in necrotic core
and percentage atheroma volume has not been
assessed.
Conclusions
In non-culprit vessels, large baseline and necrotic
core rich plaques are associated with a decrease in
percentage of necrotic core at 1 year. Patients with
acute coronary syndrome are more likely to have a
decrease in necrotic core. In these analyses and after
adjustment for other variables, treatment with dara-
pladib was associated with a decrease in percentage
necrotic core, but failed to be associated with a
decrease in percentage atheroma volume. On the
contrary, statin use was only associated with a
decrease in percentage atheroma volume.
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Appendix
Core Laboratories: Imaging (Cardialysis, Rotterdam,
The Netherlands).
Participating Centers (number of patients
enrolled): Austria: Hanusch Krankenhaus, Georg
Gaul (6). Belgium: Centre Hospitalier Universitaire
Sart-Tilman, Victor Legrand (10); ZNA Campus
Middelheim, Stefan Verheye (25); Cardiovascular
Center, Aalst, William Wijns (14). Czech Republic:
Vsˇeobecna´ Fakultnı´ Nemocnice, Michael Ascher-
mann (23). Denmark: Skejby University Hospital,
Hans Erik Bøtker (18). Germany: West German
Heart Center, Raimund Erbel (7); Kerckhoff Klinik,
Christian Hamm (7); Universita¨tsklinikum Heidel-
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